Form 4: NeuroOne Medical Technologies CEO David Rosa Disposes of Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


NeuroOne Medical Technologies CEO David Rosa disposed of 2,458 shares of common stock on March 31, 2025, to cover tax obligations.

Summary

  • On March 31, 2025, David A. Rosa, CEO and President of NeuroOne Medical Technologies Corp, disposed of 2,458 shares of common stock.
  • The transaction was executed at a price of $0.8502 per share.
  • This disposal was to cover tax obligations.
  • Following the transaction, Rosa directly owns 1,061,289 shares of NeuroOne Medical Technologies Corp.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider transaction. The sentiment is neutral as it simply reports a transaction.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This transaction is a common occurrence where executives sell shares to cover tax obligations.

Stakeholder Impact

  • The disposal of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is a common practice to cover tax obligations.

Key Dates

DateDescription
03/31/2025Date of transaction: David Rosa disposed of shares.
04/02/2025Date of signature on the Form 4 filing.

Keywords

Form 4, NeuroOne Medical Technologies, NMTC, David A. Rosa, Stock Disposal, Tax Obligations, Insider Trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.